Supplementary Data — Antiandrogens reduce COVID-19 risk: real-time meta-analysis of 49 studies

October 2026

Antiandrogen COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Cadegiani77%0.23 · 0.08–0.66recov. time8 (n)262 (n) Cadegiani83%0.17 · 0.06–0.51recov. time8 (n)262 (n) Cadegiani38%0.62 · 0.42–0.91viral time8 (n)262 (n) McCoy (DB RCT)80%0.20 · 0.01–4.13death0/1342/134censored, see details CS3 McCoy (DB RCT)97%0.03 · 0.00–0.47ventilation0/13417/134censored, see details CS3 McCoy (DB RCT)91%0.09 · 0.03–0.27hosp.3/13435/134censored, see details CS3 Cadegiani (DB RCT)62%0.38 · 0.18–0.82no recov.7/4418/43 Cadegiani (DB RCT)44%0.56 · 0.40–0.79recov. time44 (n)43 (n) Cadegiani (DB RCT)40%0.60 · 0.44–0.81recov. time44 (n)43 (n) Cadegiani (DB RCT)63%0.37 · 0.02–8.85death0/751/102 Cadegiani (DB RCT)90%0.10 · 0.01–1.84ventilation0/755/102 Cadegiani (DB RCT)86%0.14 · 0.03–0.60hosp.2/7519/102 Kintor (DB RCT)67%0.33 · 0.01–8.16death0/3651/365 Kintor (DB RCT)50%0.50 · 0.15–1.65hosp.4/3658/365 Kintor (DB RCT)67%0.33 · 0.01–8.16death0/3601/361 Kintor (DB RCT)71%0.29 · 0.06–1.37hosp.2/3607/361 Kintor (DB RCT)67%0.33 · 0.01–8.16death0/3461/347 Kintor (DB RCT)92%0.08 · 0.00–1.36hosp.0/3466/347 Kintor (DB RCT)74%0.26 · 0.13–0.51viral+365 (n)365 (n) Hunt39%0.61 · 0.51–0.73death167/1,7881,445/24,720 Vicenzi93%0.07 · 0.04–0.53death30 (n)39 (n)OT1 Vicenzi81%0.19 · 0.07–0.53death/int.30 (n)39 (n)OT1 Goren81%0.19 · 0.03–1.28ICU1/1217/36 Goren86%0.14 · 0.02–0.94ICU1/1238/65 Goren−50%1.50 · 0.15–15.11death1/122/36 Goren−35%1.35 · 0.17–11.09death1/124/65 Mareev (RCT)11%0.89 · 0.65–1.22no recov.33 (n)33 (n)CT2 Mareev (RCT)39%0.61 · 0.14–0.97no recov.14/2420/21CT2 Mareev (RCT)8%0.92 · 0.77–1.09hosp. time33 (n)33 (n)CT2 Mareev (RCT)87%0.13 · 0.01–2.25viral+0/173/13CT2 Zarehoseinz.. (RCT)75%0.25 · 0.03–2.14death1/404/40 Zarehoseinz.. (RCT)0%1.00 · 0.06–15.44ICU1/401/40 Ghandehari (RCT)−22%1.22 · 0.08–18.20death1/181/22 Ghandehari (RCT)85%0.15 · 0.01–2.82ventilation0/183/22 Ghandehari (RCT)76%0.24 · 0.03–1.91progression1/185/22 Ghandehari (RCT)39%0.61 · 0.18–2.11progression3/186/22 Ersoy (ICU)46%0.54 · 0.36–0.81death14/3026/30ICU patients Welén (RCT)80%0.20 · 0.01–4.65death0/291/10 Welén (RCT)31%0.69 · 0.07–6.81ventilation2/291/10 Welén (RCT)−133%2.33 · 1.06–5.00no disch.29 (n)10 (n) Welén (RCT)−50%1.50 · 1.10–2.04hosp. time29 (n)10 (n) Cadegiani (DB RCT)78%0.22 · 0.16–0.30death45/423171/355 Cadegiani (DB RCT)79%0.21 · 0.15–0.30death34/423138/355 Cadegiani (DB RCT)45%0.55 · 0.49–0.62no recov.423 (n)355 (n) Cadegiani (DB RCT)55%0.45 · 0.39–0.52no recov.423 (n)355 (n) Cadegiani (DB RCT)33%0.67 · 0.54–0.82hosp. time423 (n)355 (n) Davarpanah78%0.22 · 0.08–0.55hosp.6/10323/103CT2 Davarpanah67%0.33 · 0.16–0.71progression8/10324/103CT2 Davarpanah64%0.36 · 0.21–0.60recov. time103 (n)103 (n)CT2 Kotfis (RCT)17%0.83 · 0.25–2.74death4/245/25 Kotfis (RCT)11%0.89 · 0.35–2.28ICU6/247/25 Kotfis (RCT)30%0.70 · 0.24–2.01TFS24 (n)25 (n) Abbasi (SB RCT)55%0.45 · 0.18–1.13death5/5119/87 Abbasi (SB RCT)34%0.66 · 0.30–1.48ventilation7/5118/87 Abbasi (SB RCT)19%0.81 · 0.42–1.59ICU10/5121/87 Abbasi (SB RCT)47%0.53 · 0.39–0.72no recov.51 (n)87 (n) Gomaa (DB RCT)91%0.09 · 0.01–1.56death0/255/25CT2 Gomaa (DB RCT)91%0.09 · 0.01–1.56ventilation0/255/25CT2 Gomaa (DB RCT)44%0.56 · 0.40–0.79recov. time25 (n)25 (n)CT2 Gomaa (DB RCT)33%0.67 · 0.52–0.85no recov.25 (n)25 (n)CT2 Hsieh88%0.12 · 0.01–2.22death0/1174/143CT2 Hsieh51%0.49 · 0.10–2.47ventilation2/1175/143CT2 Hsieh30%0.70 · 0.21–2.33ICU4/1177/143CT2 Hsieh88%0.12 · 0.01–2.22no recov.0/1174/143CT2 Hsieh36%0.64 · 0.51–0.80viral load117 (n)143 (n)CT2 Nickols (DB RCT)18%0.82 · 0.32–1.82death11/627/34HITCH Nickols (DB RCT)−19%1.19 · 0.50–2.84ventilation13/626/34HITCH Nickols (DB RCT)−17%1.17 · 0.50–2.28no recov.15/627/34HITCH Nickols (DB RCT)−20%1.20 · 0.02–92.12hosp. time62 (n)34 (n)HITCH Gordon (DB RCT)82%0.18 · 0.03–0.94deathn/an/a Gordon (DB RCT)76%0.24 · 0.03–1.63ventilation timen/an/a Gordon (DB RCT)73%0.27 · 0.09–0.86ICUn/an/a Nicastri (DB RCT)52%0.48 · 0.08–2.70oxygen20 (n)19 (n) Nicastri (DB RCT)7%0.93 · 0.18–4.76oxygen22 (n)19 (n) Nicastri (DB RCT)−4%1.04 · 0.20–5.26oxygen20 (n)19 (n) Nicastri (DB RCT)40%0.60 · 0.11–2.94oxygen22 (n)19 (n) Nicastri (DB RCT)69%0.31 · 0.05–1.85viral+20 (n)19 (n) Nicastri (DB RCT)10%0.90 · 0.18–4.55viral+22 (n)19 (n) Wadhwa (RCT)72%0.28 · 0.09–0.85progression4/749/46 Wadhwa (RCT)49%0.51 · 0.27–0.95no disch.13/7416/46 Wadhwa (RCT)18%0.82 · 0.67–1.00recov. time74 (n)46 (n) Barnette (DB RCT)55%0.45 · 0.27–0.74death19/9423/51 Barnette (DB RCT)49%0.51 · 0.33–0.76ventilation time98 (n)52 (n) Barnette (DB RCT)44%0.56 · 0.40–0.80ICU98 (n)52 (n) Barnette (DB RCT)26%0.74 · 0.57–0.97hosp. time98 (n)52 (n) Montopoli95%0.05 · 0.00–0.77death0/5,27318/37,161 Montopoli75%0.25 · 0.09–0.76severe case1/5,27331/37,161 Montopoli75%0.25 · 0.09–0.65cases4/5,273114/37,161 Holt−129%2.29 · 1.59–3.32death/ICU16/31148/658 Koskinen46%0.54 · 0.06–5.16death1/1343/218 Koskinen46%0.54 · 0.06–5.16death/ICU1/1343/218 Koskinen11%0.89 · 0.34–2.34cases6/13411/218 Patel55%0.45 · 0.11–1.47death4/2210/36 Patel69%0.31 · 0.05–1.81ventilation22 (n)36 (n) Patel77%0.23 · 0.06–0.79hosp.22 (n)36 (n) Bennani95%0.05 · 0.00–2063death0/418/114 Bennani−119%2.19 · 0.37–12.91ICU1/413/114 Bennani25%0.75 · 0.28–2.02hosp.2/476/114 Bennani8%0.92 · 0.16–5.15severe case1/431/114 Ianhez80%0.20 · 0.01–2.78ICU1/1728/357 Ianhez66%0.34 · 0.04–2.31hosp.2/1764/357 Ianhez−1%1.01 · 0.63–1.64cases17/571357/12,161 Lazzeri−23%1.23 · 0.81–1.87death/ICU Kwon21%0.79 · 0.10–6.40death1/7997/4,412 Kwon−18%1.18 · 0.70–1.96cases18/79979/4,412 Klein−124%2.24 · 0.86–5.85death6/30413/1,475 Klein7%0.93 · 0.55–1.56cases17/30485/1,475 Jeon77%0.23 · 0.08–0.64casescase-control study Shaw (PSM)6%0.94 · 0.90–0.98cases47 (n)97 (n) Israel38%0.62 · 0.41–0.91hosp.case-control study Jiménez-Alcaide33%0.67 · 0.26–1.74death3/1117/50 Jiménez-Alcaide−8%1.08 · 0.54–1.83progression11 (n)50 (n) Jiménez-Alcaide−68%1.68 · 0.90–3.16cases11/15650/1,193 Kazan−229%3.29 · 0.61–17.73hosp.4/1382/227 Kazan29%0.71 · 0.39–1.32cases13/13830/227 Schmidt (PSM)20%0.80 · 0.46–1.34death25/16944/308 Schmidt (PSM)2%0.98 · 0.61–1.56severe case169 (n)308 (n) Duarte11%0.89 · 0.59–1.11death100/15632/43 Welén2%0.98 · 0.61–1.59death21/358167/4,980 Welén11%0.89 · 0.54–1.46death20/334167/4,980 Welén−151%2.51 · 1.52–4.16death24/152167/4,980 Welén−28%1.28 · 0.82–1.99ICU24/358216/4,980 Welén13%0.87 · 0.51–1.48ICU16/334216/4,980 Welén21%0.79 · 0.34–1.86ICU6/152216/4,980 Welén−23%1.23 · 0.96–1.56hosp.126/3581,108/4,980 Welén−24%1.24 · 0.97–1.59hosp.126/3341,108/4,980 Welén−40%1.40 · 0.98–1.99hosp.66/1521,108/4,980 Gedeborg−25%1.25 · 0.95–1.65deathcase-control study Lyon17%0.83 · 0.42–1.63death15/94419/994 Lyon7%0.93 · 0.86–1.00cases399/944446/994 Lee (PSW)21%0.79 · 0.62–0.97severe case76/295727/2,427 Lee (PSW)11%0.89 · 0.82–0.95cases295/3,0572,427/36,096 MacFadden7%0.93 · 0.88–0.98casesn/an/a Shah−16%1.16 · 0.68–1.98death148 (n)317 (n) Shah19%0.81 · 0.25–2.66ventilation148 (n)317 (n) Shah−3%1.03 · 0.57–1.87severe case148 (n)317 (n) Shah4%0.96 · 0.52–1.77hosp.148 (n)317 (n) Cousins (PSM)81%0.19 · 0.06–0.65ventilation731 (n)731 (n) Cousins (PSM)66%0.34 · 0.17–0.68ICU731 (n)731 (n) Davidsson2%0.98 · 0.55–1.69IgG+30/22445/431 Cousins (PSM)18%0.82 · 0.71–0.93death390/12,504479/12,504 Cousins (PSM)12%0.88 · 0.79–0.99death521/16,324592/16,324 Cousins (PSM)15%0.85 · 0.77–0.94death671/20,690783/20,690 Cousins (PSM)17%0.83 · 0.77–0.91ventilation936/12,5041,118/12,504 Cousins (PSM)17%0.83 · 0.77–0.89ventilation1,212/16,3241,459/16,324 Cousins (PSM)10%0.90 · 0.84–0.95ventilation1,524/20,6901,701/20,690
00.511.52+
1 OT: comparison with other treatment
2 CT: study uses combined treatment
3 CS: censored, see details
Rotate screen for more detailsIncrease width for more details
← Antiandrogens
reduce risk
Antiandrogens
increase risk →
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.